| Crohn Disease
Entyvio vs Remicade
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Entyvio vs Remicade with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRemicade has a higher rate of injection site reactions vs Entyvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Remicade but not Entyvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Entyvio
Remicade
At A Glance
IV infusion or SC injection
Every 2 weeks (SC) or every 8 weeks (IV)
alpha4beta7 integrin antagonist
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Indications
- Ulcerative Colitis
- Crohn Disease
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Ulcerative Colitis, Crohn Disease Week 0 and Week 2: 300 mg IV infusion over approximately 30 minutes; Week 6 onwards: 300 mg IV infusion every 8 weeks or 108 mg SC injection every 2 weeks; discontinue if no evidence of therapeutic benefit by Week 14.
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
Contraindications
- Known serious or severe hypersensitivity reaction to vedolizumab or any excipient (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased heart rate)
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
Adverse Reactions
Most common (>=3%) nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities
Serious infusion-related reactions including anaphylaxis, infections (anal abscess, sepsis, tuberculosis, Listeria meningitis, giardiasis, cytomegaloviral colitis), liver injury (elevated transaminases, hepatitis), malignancies
Postmarketing anaphylaxis, acute pancreatitis, interstitial lung disease, pneumonitis
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Pharmacology
Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue; the mechanism is gut-selective and does not affect the alpha4beta1 or alphaEbeta7 integrins or VCAM-1 interactions.
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Entyvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
UnitedHealthcare
Entyvio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Entyvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Remicade.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EntyvioView full Entyvio profile
RemicadeView full Remicade profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.